

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF ILLINOIS
EASTERN DIVISION

RECEIVED

SEP 19 2008

Judge David H. Coar
United States District Court

FEDERAL TRADE COMMISSION,)
)
Plaintiff,)
)
v.)
)
NU-GEN NUTRITION, INC.,)
)
VITASALUS, INC., and)
)
ROBERT CLOUTIER,)
)
Defendants.)
)

Judge David H. Coar

Case No. 08CV5309

**STIPULATED FINAL ORDER FOR
AGREED PERMANENT
INJUNCTION AND
SETTLEMENT OF CLAIMS FOR
MONETARY RELIEF**

Plaintiff Federal Trade Commission (“FTC” or “Commission”) filed a Complaint for Permanent Injunction and Other Equitable Relief against Nu-Gen Nutrition, Inc., Vitasalus, Inc., and Robert Cloutier, pursuant to Section 13(b) of the Federal Trade Commission Act (“FTC Act”), 15 U.S.C. § 53(b). The Complaint alleges that Defendants engaged in unfair and deceptive acts or practices in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52. The Defendants deny the allegations in the Complaint, except jurisdictional facts, but are willing to agree to entry of the following Stipulated Final Order for Agreed Permanent Injunction and Settlement of Claims for Monetary Relief (“Order”), without adjudication of any issues of fact or law.

The Commission and Defendants have stipulated to the entry of the following Order in settlement of the Commission’s Complaint against Defendants. The Court, being advised in the premises, finds:

FINDINGS

1. This Court has jurisdiction over the subject matter of this case and jurisdiction over all parties. Venue in the Northern District of Illinois is proper.
2. The Commission's Complaint states a claim upon which relief may be granted against Defendants, and the Commission has the authority to seek the relief it has requested.
3. The alleged activities of Defendants are in or affecting commerce, as defined in Section 4 of the FTC Act, 15 U.S.C. § 44.
4. Defendants waive all rights to seek judicial review or otherwise challenge or contest the validity of this Order. Defendants further waive and release any claims they may have against the Commission, its employees, representatives or agencies.
5. Defendants agree that this Order does not entitle them to seek or obtain attorneys' fees as a prevailing party under the Equal Access to Justice Act, 28 U.S.C. § 2412, as amended by Pub. L. 104-121, 110 Stat. 847, 863-64 (1996), and Defendants further waive any right to attorneys' fees that may arise under said provision of laws.
6. Each party shall bear its own costs and attorneys' fees.
7. Entry of this Order is in the public interest.
8. This Order reflects the negotiated settlement agreement of the parties.
9. Defendants expressly deny any wrongdoing or liability for any of the matters alleged in the Complaint. There have been no findings or admissions of wrongdoing or liability by the Defendants.

ORDER
DEFINITIONS

For purposes of this Order, the following Definitions shall apply:

1. “Nu-Gen Nutrition” means Nu-Gen Nutrition, Inc., a Michigan corporation with its registered office at 1301 Rankin Drive, Troy, MI 48083, its divisions and subsidiaries, and its successors and assigns.
2. “Vitasalus” means Vitasalus, Inc., a Michigan corporation with its registered office at 1301 Rankin Drive, Troy, MI 48083, its divisions and subsidiaries, and its successors and assigns.
3. “Robert Cloutier” means Robert Cloutier, individually and as an officer, director, and manager of Nu-Gen Nutrition and Vitasalus.
4. Unless otherwise specified, “Defendants” mean Nu-Gen Nutrition, Vitasalus, and Robert Cloutier.
5. “Competent and reliable scientific evidence” means tests, analyses, research, studies, or other evidence based on the expertise of professionals in the relevant area, that have been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results.
6. “Food” and “drug” mean as defined in Section 15 of the FTC Act, 15 U.S.C. § 55.
7. “Commerce” means as defined in Section 4 of the FTC Act, 15 U.S.C. § 44.
8. The term “including” in this Order means “without limitation.”
9. The terms “and” and “or” in this Order shall be construed conjunctively or disjunctively as necessary, to make the applicable phrase inclusive rather than exclusive.

10. "Endorsement" means as defined in 16 C.F.R. § 255.0(b).

PROHIBITED REPRESENTATIONS

Representations and Endorsements

I.

IT IS HEREBY ORDERED that Defendants, directly or through any corporation, partnership, subsidiary, division, trade name, or other device, and their officers, agents, servants, employees, attorneys, and all persons or entities in active concert or participation with them who receive actual notice of this Order, by personal service or otherwise, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of Cantron, programs containing Cantron, Apricot Kernels, or any similar program or products, are hereby permanently restrained and enjoined from making any representation, in any manner, expressly or by implication, including through the use of product names or endorsements, that such program or product:

- A. Treats or cures any type of cancer; or
- B. Reduces or eliminates cancer tumors;

unless the representation is true, non-misleading, and, at the time it is made, Defendants possess and rely upon competent and reliable scientific evidence that substantiates the representation.

II.

IT IS FURTHER ORDERED that Defendants, directly or through any corporation, partnership, subsidiary, division, trade name, or other device, and their officers, agents, servants, employees, attorneys, and all persons or entities in active concert or participation with them who receive actual notice of this Order, by personal service or otherwise, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any food, drug, dietary supplement, or any other health-related product,

service, or program, whether sold individually or as part of a program, are hereby permanently enjoined from making any representation, in any manner, expressly or by implication, about the absolute or comparative benefits, performance, efficacy, safety, or side effects of such product, program, or service unless the claim is true, non-misleading, and, at the time it is made, Defendants possess and rely upon competent and reliable scientific evidence that substantiates the representation.

MISREPRESENTATIONS OF TESTS OR STUDIES

III.

IT IS FURTHER ORDERED that Defendants, directly or through any corporation, partnership, subsidiary, division, trade name, or other device, and their officers, agents, servants, employees, attorneys, and all persons or entities in active concert or participation with them who receive actual notice of this Order, by personal service or otherwise, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any food, drug, dietary supplement, or any other health-related product, service, or program, whether sold individually or as part of a program, in or affecting commerce, are hereby permanently restrained and enjoined from misrepresenting, in any manner, expressly or by implication, including through the use of any product name or endorsement, the existence, contents, validity, results, conclusions, or interpretations of any test or study.

FDA APPROVED CLAIMS

IV.

IT IS FURTHER ORDERED that:

- A. Nothing in this Order shall prohibit Defendants from making any representation for any drug that is permitted in labeling for such drug under any tentative or

final standard promulgated by the Food and Drug Administration, or under any new drug application approved by the Food and Drug Administration; and

- B. Nothing in this Order shall prohibit Defendants from making any representation for any product that is specifically permitted in labeling for such product by regulations promulgated by the Food and Drug Administration pursuant to the National Labeling and Education Act of 1990.

CUSTOMER LISTS

V.

IT IS FURTHER ORDERED that:

- A. Defendants shall, within fourteen (14) days after service of this Order upon Defendants, deliver to the Commission a list, in the form of a sworn affidavit, of all consumers who purchased Cantron, Cantron-containing programs, or Apricot Kernels from them from February 2005 through the date of entry of this Order. Such list shall include each consumer's name and address, the product(s) purchased, the total amount of monies paid less any amount credited for returns or refunds, and, if available, the consumer's telephone number and email address; *provided that* the FTC shall maintain the confidentiality of the foregoing customer information and shall not use or disclose it for purposes other than the enforcement of this Order or as otherwise required by law or court order, *provided, however*, that nothing in this provision shall impose any restrictions on the use or disclosure by the FTC of confidential material as provided by: (1) the FTC's Rules of Practice and any cases construing them; (2) Sections 6(f) and 21 of the FTC Act and

any cases so construing them; and (3) any other legal obligation imposed upon the FTC; and

- B. Except as provided in this Order, Defendants, and their officers, agents, servants, employees, and attorneys and all other person or entities who receive actual notice of this Order by personal service or otherwise, are permanently restrained and enjoined from selling, renting, leasing, transferring, or otherwise disclosing the name, address, telephone number, credit card number, bank account number, email address, or other identifying information of any person who paid any money to any Defendant, at any time prior to entry of this Order, in connection with the purchase of Cantron, Cantron-containing programs, Apricot Kernels, or any other health-related product, program, or service. *Provided, however,* that Defendants may disclose such identifying information as required in Subparagraph A above, or to any law enforcement agency, or as required by any law, regulation, or court order.

NOTIFICATION TO CONSUMERS

VI.

IT IS FURTHER ORDERED that within forty-five (45) days after the date of entry of this Order, Defendants shall send by first class mail, postage prepaid, an exact copy of the notice attached as Attachment A to all persons identified in Section V.A of this Order. The mailing shall not include any other documents.

MONETARY JUDGMENT AND REDRESS TO CONSUMERS

VII.

IT IS FURTHER ORDERED that:

A. Judgment is hereby entered against Defendants, jointly and severally, in the amount of Eight Hundred Thirty Thousand Four Hundred and Thirty Four Dollars (\$830,434) for redress to consumers. *Provided, however*, that this judgment shall be subject to the conditions set forth in Section VIII (Right to Reopen); and, *provided further*, that this judgment amount shall be suspended upon Defendants' fulfillment of the payment obligations set forth below in Section VII.B.

B. Defendants shall pay to the Commission Two Hundred and Forty Six Thousand Dollars (\$246,000.00) in United States currency. Payment shall be made to the Commission within fourteen days of the date of entry of this Order by wire transfer in accord with instructions that will be provided by the Commission not later than five (5) days after the date of entry of this Order.

C. If Defendants fully comply with the payment obligation set forth in Section VII.B, the monetary judgment established by this Order shall be deemed satisfied. If Defendants do not fulfill, or only partially fulfill, the payment obligation set forth in Section VII.B: (1) the suspension of the \$830,434 judgment amount set forth in Section VII.A shall be vacated and the full amount of that judgment shall immediately become due, plus interest from the date of entry of this Order pursuant to 28 U.S.C. § 1961, less any payments or transfers already made to the FTC; and (2) Defendants waive any right to contest any allegations in the FTC's Complaint and the facts as alleged in the FTC's Complaint filed in this action must be taken as true in any subsequent litigation filed by the FTC to collect such unpaid amount, including, but not limited to, a non-

dischargeability complaint filed in any bankruptcy case; *provided, however, further*, that in the event Defendants do not comply with any provision of this Order, including any provision set forth in this Section, this subsection does not prevent the FTC from seeking an order to show cause why Defendants should not be held in contempt for failure to comply with the Order provision.

D. All funds paid pursuant to this Order shall be deposited into a fund administered by the Commission or its agents to be used for equitable relief, including but not limited to redress to consumers, and any attendant expenses for the administration of such equitable relief. In the event that direct redress to consumers is wholly or partially impracticable or funds remain after the redress is completed, the Commission may apply any remaining funds for such other equitable relief (including consumer information remedies) as it determines to be reasonably related to Defendants' practices as alleged in the Complaint. Any funds not used for such equitable relief shall be deposited to the United States Treasury as disgorgement. Defendants shall have no right to challenge the Commission's choice of remedies under this Part. Defendants shall have no right to contest the manner of distribution chosen by the Commission. No portion of any payment under this Order shall be deemed a payment of any fine, penalty, or punitive assessment.

E. Defendants relinquish all dominion, control, and title to the funds paid, and all legal and equitable title to the funds vests in the Treasurer of the United States and in the designated consumers. Defendants shall make no claim to or demand for return of the funds, directly or indirectly, through counsel or otherwise; and in the event of bankruptcy of any Defendant, Defendants acknowledge that the funds are not part of the debtor's estate, nor does the estate have any claim or interest therein.

F. In accordance with 31 U.S.C. § 7701, Defendants are hereby required, unless they have done so already, to furnish to the Commission their taxpayer identifying numbers (or social security numbers or employer identification numbers), which shall be used for purposes of collecting and reporting on any delinquent amount arising out of this Order. Defendant Robert Cloutier is further required, unless he has already done so, to provide the Commission with clear, legible, and full-size photocopies of all valid driver's licenses that he possesses, which will be used for reporting and compliance purposes.

G. Proceedings instituted under this Paragraph are in addition to, and not in lieu of, any other civil or criminal remedies that may be provided by law, including any other proceedings the Commission may initiate to enforce this Order.

RIGHT TO REOPEN

VIII.

IT IS FURTHER ORDERED that:

A. Within ten (10) business days after the date of entry of this Stipulated Order by the Court, Defendants shall each submit to the Commission a truthful sworn statement that shall reaffirm and attest to the truthfulness, accuracy, and completeness of their respective financial statements, submitted to the Commission by Defendants Nu-Gen Nutrition and Robert Cloutier on June 11, 2008 and by Defendant Vitasalus on June 20, 2008, as well as follow-up information provided in, and attached to, letters from Daniel Hurtado dated June 18, 2008, June 24, 2008, June 25, 2008 and June 27, 2008, and an email message from Daniel Hurtado dated June 30, 2008. The FTC's agreement to this Stipulated Order is expressly premised upon the truthfulness, accuracy, and

completeness of Defendants' financial condition, as represented in the financial statements and documents referenced above.

B. If upon motion by the FTC, with notice to the Defendants and an opportunity to respond, the Court finds that a Defendant failed to submit the sworn statements required by this Section, or that a Defendant failed to disclose any material asset, made a material misrepresentation regarding the value of an asset, or made any other material misrepresentation or omission in the sworn financial statements and any supporting documents, the Court shall enter judgment against such Defendant in favor of the FTC in the amount of \$830,434.00, and the entire amount of the judgment shall become immediately due and payable, less any amount already paid, and interest computed at the rate prescribed under 28 U.S.C. § 1961 shall immediately begin to accrue on the unpaid balance. *Provided, however,* that in all other respects, this judgment shall remain in full force and effect, unless otherwise ordered by the Court. *Provided further that* proceedings instituted under this provision would be in addition to, and not in lieu of, any other civil or criminal remedies as may be provided by law, including, but not limited to, contempt proceedings, or any other proceedings that the FTC may initiate to enforce this Order. For purposes of this Section, and any subsequent proceedings to enforce payment, including but not limited to a non-dischargeability complaint filed in a bankruptcy proceeding, Defendants agree not to contest any of the allegations in the FTC's Complaint.

COMPLIANCE MONITORING

IX.

IT IS FURTHER ORDERED that, for purposes of monitoring and investigating compliance with any provision of this Order:

- A. Within ten (10) days of receipt of written notice from a representative of the Commission, Defendants each shall submit additional written reports, sworn to under penalty of perjury; produce documents for inspection and copying; appear for deposition; and/or provide entry during normal business hours to any business location in such Defendant's possession or direct or indirect control to inspect the business operations;
- B. In addition, the Commission is authorized to monitor compliance with this Order by all lawful means, including, but not limited to the following:
1. Obtaining discovery from any person, without further leave of the Court, using the procedures prescribed by Fed. R. Civ. P. 30, 31, 33, 34, 36, and 45;
 2. Posing as consumers and clients to any Defendant, employees of any Defendant, or any other entity managed or controlled in whole or in part by any Defendant, without the necessity of identification or prior notice; and
- C. Defendants shall permit representatives of the Commission to interview any employer, consultant, independent contractor, representative, agent, or employee who has agreed to such an interview, relating in any way to conduct subject to this Order. The person interviewed may have counsel present.

Provided, however, that nothing in this Order shall limit the Commission's lawful use of compulsory process, pursuant to Sections 9 and 20 of the FTC Act, 15 U.S.C. §§ 49, 57b-1, to obtain any documentary material, tangible things, testimony, or information

relevant to unfair or deceptive acts or practices in or affecting commerce (within the meaning of 15 U.S.C. § 45(a)(1)).

COMPLIANCE REPORTING BY DEFENDANTS

X.

IT IS FURTHER ORDERED that, in order that compliance with the provisions of this Order may be monitored:

- A. For a period of three (3) years from the date of entry of this Order,
 1. Defendant Robert Cloutier shall notify the Commission of the following:
 - a. Any changes in Defendant's residence(s), mailing address(es), and telephone number(s) within ten (10) days of the date of such change;
 - b. Any changes in Defendant's employment status (including self employment) and any change in Defendant's ownership in any business entity, within ten (10) days of such change. Such notice shall include the name and address of each business that the Defendant is affiliated with, employed by, creates or forms, or performs services for; a statement of the nature of the business; and a statement of the Defendant's duties and responsibilities in connection with the business or employment; and
 - c. Any changes in the Defendant's name or use of any aliases or fictitious names; and

2. Defendants shall notify the Commission of any proposed change in corporate structure of Defendants Nu-Gen Nutrition and Vitasalus or any business entity that any Defendant directly or indirectly controls, or has an ownership interest in, that may affect compliance obligations arising under this Order, including, but not limited, to a dissolution, assignment, sale, merger, or other action that would result in the emergence of a successor entity; the creation or dissolution of a subsidiary, parent, or affiliate that engages in any acts or practices subject to this Order; the filing of a bankruptcy petition; or a change in the corporate or business entity's name or address, at least thirty (30) days prior to such change, *provided that*, with respect to any proposed change in the corporation about which a Defendant learns less than thirty (30) days prior to the date such action is to take place, the Defendant shall notify the Commission as soon as is practicable after obtaining such knowledge.

B. Sixty (60) days after the date of entry of this Order, Defendants each shall provide a written report to the Commission, sworn to under penalty of perjury, setting forth in detail the manner and form in which they have complied and are complying with this Order. This report shall include, but not be limited to:

1. For Defendant Robert Cloutier:

a. The then-current residence addresses, mailing addresses, and telephone numbers of the Defendant;

- b. The then-current employment and business addresses and telephone numbers of the Defendant, a description of the business activities of each such employer or business, and the title and responsibilities of the Defendant, for each such employer or business. For purposes of this Paragraph, “employment” includes the performance of services as an employee, consultant, or independent contractor; and “employers” include any individual or entity for whom the Defendant performs services as an employee, consultant, or independent contractor;
 - c. A copy of each acknowledgment of receipt of this Order obtained by the Defendant pursuant to Paragraph XII; and
 - d. Any other change required to be reported under Subparagraph A of this Paragraph.
2. For Defendants Nu-Gen Nutrition and Vitasalus:
- a. A copy of each acknowledgment of receipt of this Order obtained by each Defendant pursuant to Paragraph XII; and
 - b. Any other changes required to be reported under Subparagraph A of this Section.
- C. For purposes of this Order, Defendants each shall, unless otherwise directed by the Commission’s authorized representatives, mail all written notifications to the Commission to:

Associate Director for Enforcement
Federal Trade Commission

601. New Jersey Avenue, N.W.,
Washington, D.C. 20580
Re: FTC v. Nu-Gen Nutrition, Inc. et al., Civil Action

- D. For purposes of the compliance reporting required by this Paragraph, the Commission is authorized to communicate directly with any Defendant.

RECORD KEEPING PROVISIONS

XI.

IT IS FURTHER ORDERED that, for a period of six (6) years from the date of entry of this Order, Defendants Nu-Gen Nutrition and Vitasalus and any business in which Defendant Robert Cloutier is a majority owner or otherwise directly or indirectly controls the business are hereby restrained and enjoined from failing to create and retain the following records:

- A. Accounting records that reflect the cost of any goods or services sold, revenues generated, and disbursement of such revenues;
- B. Personnel records accurately reflecting: the name, address, and telephone number of each person employed in any capacity by such business, including as an independent contractor; that person's job title or position; the date upon which the person commenced work; and the date and reason for the person's termination, if applicable;
- C. Customer files containing the names, addresses, telephone numbers, dollar amounts paid, quantity of items or services purchased, and description of items or services purchased, to the extent such information is obtained in the ordinary course of business;

- D. Complaints and refund requests (whether received directly, indirectly, or through any third party) and all records showing any responses to those complaints or requests;
- E. Copies of all advertisements, promotional materials, sales scripts, training materials, or other marketing materials utilized in the advertising, marketing, promotion, offering for sale, distribution, or sale of any program or product covered by this Order;
- F. All materials that were relied upon in making any representations contained in the materials identified in Subparagraph E above, including all documents evidencing or referring to the accuracy or any claim therein or to the benefits, performance, efficacy, safety, or side effects of any program or product, including but not limited to all tests, reports, studies, demonstrations, as well as well evidence that confirms, contradicts, qualifies, or calls into question the accuracy of such claims regarding the benefits, performance, efficacy, safety, or side effects of such program or product; and
- G. All records and documents necessary to demonstrate full compliance with each provision of this Order, including but not limited to, copies of acknowledgments of receipt of this Order and all reports submitted to the FTC pursuant to this Order.

DISTRIBUTION OF ORDER

XII.

IT IS FURTHER ORDERED that, for a period of five (5) years from the date of entry of this Order, Defendants shall deliver copies of the Order as directed below:

- A. Defendants Nu-Gen Nutrition and Vitasalus shall deliver a copy of this Order to each of its principals, officers, directors, and managers. Defendants Nu-Gen Nutrition and Vitasalus also shall deliver a copy of the Order to all of its employees, agents, and representatives who engage in conduct related to the subject matter of this Order. For current personnel, delivery shall be within five (5) days of service of this Order upon Defendants. For new personnel, delivery shall occur- prior- to their assuming their responsibilities.
- B. For any business that Defendant Robert Cloutier controls, directly or indirectly, or in which he has a majority ownership interest, Defendant Robert Cloutier must deliver a copy of this Order to all of the principals, officers, directors, and managers of that business. Defendant Robert Cloutier must also deliver copies of this Order to all employees, agents, and representatives of that business who engage in conduct related to the subject matter of this Order. For current personnel, delivery shall be within five (5) days of service of this Order upon Defendants. For new personnel, delivery shall occur prior to their assuming their responsibilities.
- C. For any business where Defendant Robert Cloutier is not a controlling person of the business but otherwise engages in conduct related to the subject

matter of this Order, he shall deliver a copy of this Order to each of the principals and managers of such business before engaging in such conduct.

- D. Defendants must secure a signed and dated statement acknowledging receipt of this Order, within thirty days of delivery, from each person receiving a copy of the Order pursuant to this Paragraph.

ACKNOWLEDGMENT OF RECEIPT OF ORDER BY DEFENDANTS


XIII.

IT IS FURTHER ORDERED that each Defendant, within five (5) business days of receipt of this Order as entered by the Court, must submit to the Commission a truthful sworn statement acknowledging receipt of this Order.

RETENTION OF JURISDICTION

XIV.

IT IS FURTHER ORDERED that this Court shall retain jurisdiction of this matter for purposes of construction, modification and enforcement of this Order.

SO ORDERED:

UNITED STATES DISTRICT JUDGE
DATED: 9/19/08

STIPULATED JUDGMENT IS THEREFORE ENTERED, pursuant to all the terms and conditions recited above.


SO STIPULATED:



STEVEN WERNIKOFF


Federal Trade Commission
55 W. Monroe St., Suite 1825
Chicago, IL 60603
312-960-5634 (Tel.)
312-960-5600 (Fax)

Attorney for Plaintiff
FEDERAL TRADE COMMISSION


NU-GEN NUTRITION, INC.


VITASALUS, INC.


ROBERT CLOUTIER, individually and
as a
principal, officer, and director of Nu-Gen
Nutrition. and Vitasalus


Daniel J. Hurtado, Esq.
Jenner & Block LLP
330 North Wabash Avenue
Chicago, IL 60611
312-222-9350 (Tel.)
312-923-2645 (Fax)
dhurtado@jenner.com

Nancy Lord, M.D., Esq.
Nancy Lord, Ltd.
1970 N. Leslie Rd., No. 220
Pahrump, NV 89060
775-751-3636 (Tel.)
775-582-1301 (Fax)
nancylord@mindspring.com

ATTORNEYS FOR DEFENDANTS

ATTACHMENT A

LETTER TO BE SENT BY FIRST CLASS MAIL

[To be printed on letterhead of Nu-Gen Nutrition, Inc. d/b/a www.cancerchoices.com]

[Name and address of recipient]

[Date]

Dear [Recipient]:

We recently entered into a negotiated settlement agreement with the Federal Trade Commission ("FTC") regarding advertising claims for Cantron and Apricot Kernels. These products are sold on the www.cancerchoices.com website. The settlement with the FTC does not constitute an admission or finding that we have violated the law. As part of the settlement, however, we agreed to send you the following information prepared by the FTC about the scientific evidence on these products.

It is the FTC's position that little scientific research has been done concerning Cantron or Apricot Kernels as a treatment or cure for cancer in humans, and that the scientific studies that have been done do not demonstrate that Cantron and Apricot Kernels, or the ingredients in these products, are effective when used as treatments for cancer.

It is very important that you talk to your doctor or health care provider before using *any* alternative or herbal product, including Cantron and Apricot Kernels. Speaking with your doctor is important to make sure that all aspects of your medical treatment work together. Things that seem safe, such as certain foods, herbs, pills or pharmaceutical drugs, may interfere or affect your cancer or other medical treatment, or other medicines you might be taking. Some herbs or other complementary or alternative treatments may keep your medicines from doing what they are supposed to do, or could be harmful when taken with other medicines or in high doses. It also is very important that you talk to your doctor or health care provider before you decide to take any alternative or herbal product, including Cantron and Apricot Kernels, instead of taking conventional cancer treatments.

If you would like further information about complementary and alternative treatments for cancer, the FTC recommends the following Internet web sites:

1. The National Cancer Institute: www.cancer.gov/cancertopics/pdd ;or
2. The National Center for Complementary and Alternative Medicines: www.nccam.nih.gov

The FTC also suggests that you can contact the National Cancer Institute's Cancer Information Service at 1-800-4-CANCER or 1-800-422-6237.